Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 27, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001298709-26-000002
Filed / recorded
Mar 3, 2026, 11:30 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Krystal Biotech, Inc.
Issuer CIK
1711279
Ticker
KRYS
Reporting person
Krish S Krishnan
Relationship
Director, Officer, 10% owner
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 27, 2026
Transaction code
M
Shares / units
26,250
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,509,075
Ownership form
Direct
Amendment
No
Footnotes from the filing
52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.